股本结构
单位：万股
| 公告日期 | 2024-07-31 | 2024-08-13 | 2023-01-31 | 2022-12-30 | 2022-07-29 | 2022-06-30 |
|---|---|---|---|---|---|---|
| 证券总股本 | 2997.07 | 2700.53 | 2979.00 | 2978.63 | 2957.88 | 2955.31 |
| 普通股本 | 5994.15 | 5401.06 | 5958.01 | 5957.26 | 5915.76 | 5910.62 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-07-31 | 2024-06-30 | 2023-01-31 | 2022-12-30 | 2022-07-29 | 2022-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：2
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-07-31 | 5994.15 | 未披露 | 定期报告 | 2024-07-31 |
| 2024-08-13 | 5401.06 | 未披露 | 定期报告 | 2024-06-30 |
| 2023-01-31 | 5958.01 | 未披露 | 定期报告 | 2023-01-31 |
| 2022-12-30 | 5957.26 | 未披露 | 定期报告 | 2022-12-30 |
| 2022-07-29 | 5915.76 | 未披露 |
更多>>
During July, Calliditas Therapeutics AB (publ) has issued 51,399 ordinary shares as part of the company’s long-term incentive program for certain members of the board of directors issued in 2019
|
2022-07-29 |
| 2022-06-30 | 5910.62 | 未披露 |
更多>>
During June, Calliditas Therapeutics AB (publ) has issued 5,908,018 class C-shares as part of the establishment of the company’s at-the-market program.
|
2022-06-30 |
| 2022-06-28 | 5319.82 | 未披露 | 定期报告 | 2022-05-31 |
| 2022-05-20 | 5317.22 | 未披露 | 定期报告 | 2022-03-31 |
| 2021-08-31 | 5234.16 | 未披露 | 定期报告 | 2021-08-31 |
| 2020-09-30 | 4994.16 | 未披露 | 定期报告 | 2020-09-30 |
| 2020-06-08 | 4793.84 | 未披露 |
更多>>
1.Global Offering 9,230,770 common shares offered by us, consisting of 8,306,770 common shares in the form of 4,153,385 ADSs offered in the U.S. offering and 924,000 common shares offered in the European private placement.
2.The number of common shares (including in the form of ADSs) to be outstanding after the global offering is based on 38,707,638 common shares outstanding as of March 31, 2020
|
2020-06-05 |
During July, Calliditas Therapeutics AB (publ) has issued 51,399 ordinary shares as part of the company’s long-term incentive program for certain members of the board of directors issued in 2019
During June, Calliditas Therapeutics AB (publ) has issued 5,908,018 class C-shares as part of the establishment of the company’s at-the-market program.
1.Global Offering 9,230,770 common shares offered by us, consisting of 8,306,770 common shares in the form of 4,153,385 ADSs offered in the U.S. offering and 924,000 common shares offered in the European private placement.
2.The number of common shares (including in the form of ADSs) to be outstanding after the global offering is based on 38,707,638 common shares outstanding as of March 31, 2020